Literature DB >> 25576083

Redundancy: a critical obstacle to improving cancer therapy.

Orit Lavi1.   

Abstract

A system characterized by redundancy has various elements that are able to act in the same biologic or dynamic manner, where the inhibition of one of those elements has no significant effect on the global biologic outcome or on the system's dynamic behavior. Methods that aim to predict the effectiveness of cancer therapies must include evolutionary and dynamic features that would change the static view that is widely accepted. Here, we explore several important issues about mechanisms of redundancy, heterogeneity, biologic importance, and drug resistance and describe methodologic challenges that, if overcome, would significantly contribute to cancer research. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2015        PMID: 25576083      PMCID: PMC6250436          DOI: 10.1158/0008-5472.CAN-14-3256

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

1.  Network motifs: simple building blocks of complex networks.

Authors:  R Milo; S Shen-Orr; S Itzkovitz; N Kashtan; D Chklovskii; U Alon
Journal:  Science       Date:  2002-10-25       Impact factor: 47.728

Review 2.  Living with or without cyclins and cyclin-dependent kinases.

Authors:  Charles J Sherr; James M Roberts
Journal:  Genes Dev       Date:  2004-11-15       Impact factor: 11.361

3.  Mechanisms of multidrug resistance in cancer.

Authors:  Jean-Pierre Gillet; Michael M Gottesman
Journal:  Methods Mol Biol       Date:  2010

4.  Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases.

Authors:  Keiran S M Smalley; Nikolas K Haass; Patricia A Brafford; Mercedes Lioni; Keith T Flaherty; Meenhard Herlyn
Journal:  Mol Cancer Ther       Date:  2006-05       Impact factor: 6.261

Review 5.  Predicting drug targets and biomarkers of cancer via genome-scale metabolic modeling.

Authors:  Livnat Jerby; Eytan Ruppin
Journal:  Clin Cancer Res       Date:  2012-10-15       Impact factor: 12.531

Review 6.  Cytokine signaling through nonreceptor protein tyrosine kinases.

Authors:  T Taniguchi
Journal:  Science       Date:  1995-04-14       Impact factor: 47.728

7.  Principles and strategies for developing network models in cancer.

Authors:  Dana Pe'er; Nir Hacohen
Journal:  Cell       Date:  2011-03-18       Impact factor: 41.582

8.  Cyclosporin A is a broad-spectrum multidrug resistance modulator.

Authors:  Misbah Qadir; Kieran L O'Loughlin; Stacy M Fricke; Nicole A Williamson; William R Greco; Hans Minderman; Maria R Baer
Journal:  Clin Cancer Res       Date:  2005-03-15       Impact factor: 12.531

Review 9.  Targeting multidrug resistance in cancer.

Authors:  Gergely Szakács; Jill K Paterson; Joseph A Ludwig; Catherine Booth-Genthe; Michael M Gottesman
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

10.  Redundant control of Ultrabithorax by zeste involves functional levels of zeste protein binding at the Ultrabithorax promoter.

Authors:  J D Laney; M D Biggin
Journal:  Development       Date:  1996-07       Impact factor: 6.868

View more
  19 in total

Review 1.  Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies.

Authors:  Min Hwan Kim; Joon Kim
Journal:  Cell Mol Life Sci       Date:  2016-11-08       Impact factor: 9.261

2.  Essential Role of DNA Methyltransferase 1-mediated Transcription of Insulin-like Growth Factor 2 in Resistance to Histone Deacetylase Inhibitors.

Authors:  Hye-Young Min; Su-Chan Lee; Jong Kyu Woo; Hyun Jin Jung; Kwan Hee Park; Hae Min Jeong; Seung Yeob Hyun; Jaebeom Cho; Wooin Lee; Ji Eun Park; So Jung Kwon; Hyo-Jong Lee; Xiao Ni; Young Kee Shin; Faye M Johnson; Madeleine Duvic; Ho-Young Lee
Journal:  Clin Cancer Res       Date:  2016-08-31       Impact factor: 12.531

3.  Understanding redundancy and resilience: Redundancy in life is provided by distributing functions across networks rather than back-up systems: Redundancy in life is provided by distributing functions across networks rather than back-up systems.

Authors:  Philip Hunter
Journal:  EMBO Rep       Date:  2022-02-14       Impact factor: 8.807

4.  Development of a TNF-α-mediated Trojan Horse for bacteria-based cancer therapy.

Authors:  Che-Wei Hu; You-Chiun Chang; Cheng-Hao Liu; Yao-An Yu; Kurt Yun Mou
Journal:  Mol Ther       Date:  2022-04-18       Impact factor: 12.910

5.  Coordinated expression and genetic polymorphisms in Grainyhead-like genes in human non-melanoma skin cancers.

Authors:  Agnieszka Kikulska; Tobias Rausch; Ewa Krzywinska; Magdalena Pawlak; Bartek Wilczynski; Vladimir Benes; Piotr Rutkowski; Tomasz Wilanowski
Journal:  BMC Cancer       Date:  2018-01-04       Impact factor: 4.430

6.  Aldose reductase inhibitor increases doxorubicin-sensitivity of colon cancer cells and decreases cardiotoxicity.

Authors:  Himangshu Sonowal; Pabitra B Pal; Jian-Jun Wen; Sanjay Awasthi; Kota V Ramana; Satish K Srivastava
Journal:  Sci Rep       Date:  2017-06-09       Impact factor: 4.379

7.  Factor Analysis for Bicluster Acquisition (FABIA) revealed vincristine-sensitive transcript pattern of canine transmissible venereal tumors.

Authors:  K Chokeshaiusaha; D Puthier; C Nguyen; P Sudjaidee; T Sananmuang
Journal:  Heliyon       Date:  2019-05-14

8.  OSU-2S/Sorafenib Synergistic Antitumor Combination against Hepatocellular Carcinoma: The Role of PKCδ/p53.

Authors:  Hany A Omar; Mai F Tolba; Jui-Hsiang Hung; Taleb H Al-Tel
Journal:  Front Pharmacol       Date:  2016-11-30       Impact factor: 5.810

9.  Cancer- and behavior-related genes are targeted by selection in the Tasmanian devil (Sarcophilus harrisii).

Authors:  Jean-Noël Hubert; Tatiana Zerjal; Frédéric Hospital
Journal:  PLoS One       Date:  2018-08-13       Impact factor: 3.240

Review 10.  Neglected Functions of TFCP2/TFCP2L1/UBP1 Transcription Factors May Offer Valuable Insights into Their Mechanisms of Action.

Authors:  Agnieszka Taracha; Grzegorz Kotarba; Tomasz Wilanowski
Journal:  Int J Mol Sci       Date:  2018-09-20       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.